Phlippen, Sandra; Vermeersch, An - 2008
pharma should either build a critical mass of disease area knowledge or diversify projects over different DA’s in order to … obtain higher success probabilities. Projects in which a firm has built a critical mass of disease knowledge (through at … interpret this finding as knowledge spillovers from external to internal projects, as the limited number of external projects …